دورية أكاديمية
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
| العنوان: | Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study |
|---|---|
| المؤلفون: | Tassone, PierfrancescoAff1, Aff2, IDs13045023014688_cor1, Di Martino, Maria TeresaAff1, Aff2, Aff3, Arbitrio, MariamenaAff4, Aff2, Fiorillo, LuciaAff2, Aff3, Staropoli, NicolettaAff2, Aff3, Ciliberto, DomenicoAff2, Aff3, Cordua, Alessia, Scionti, Francesca, Bertucci, Bernardo, Salvino, AngelaAff2, Aff3, Lopreiato, Mariangela, Thunarf, Fredrik, Cuomo, Onofrio, Zito, Maria Cristina, De Fina, Maria Rosanna, Brescia, Amelia, Gualtieri, SimonaAff2, Aff3, Riillo, Caterina, Manti, Francesco, Caracciolo, Daniele, Barbieri, Vito, Di Paola, Eugenio Donato, Di Francesco, Adele Emanuela, Tagliaferri, PierosandroAff1, Aff3 |
| المصدر: | Journal of Hematology & Oncology. 16(1) |
| قاعدة البيانات: | Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!